KR20110011676A - 항-ＰｉｒＢ 항체 - Google Patents

항-ＰｉｒＢ 항체 Download PDF

Info

Publication number
KR20110011676A
KR20110011676A KR1020107027786A KR20107027786A KR20110011676A KR 20110011676 A KR20110011676 A KR 20110011676A KR 1020107027786 A KR1020107027786 A KR 1020107027786A KR 20107027786 A KR20107027786 A KR 20107027786A KR 20110011676 A KR20110011676 A KR 20110011676A
Authority
KR
South Korea
Prior art keywords
antibody
ser
leu
pirb
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020107027786A
Other languages
English (en)
Korean (ko)
Inventor
자스빈더 아타왈
마크 테시어-라빈
얀 우
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/208,883 external-priority patent/US20100047232A1/en
Priority claimed from US12/316,130 external-priority patent/US20090232794A1/en
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Publication of KR20110011676A publication Critical patent/KR20110011676A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020107027786A 2008-05-13 2009-05-13 항-ＰｉｒＢ 항체 Withdrawn KR20110011676A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US5294908P 2008-05-13 2008-05-13
US61/052,949 2008-05-13
US12/208,883 2008-09-11
US12/208,883 US20100047232A1 (en) 2006-11-14 2008-09-11 Modulators of neuronal regeneration
US12/316,130 US20090232794A1 (en) 2007-12-11 2008-12-09 Modulators of neuronal regeneration
US12/316,130 2008-12-09

Publications (1)

Publication Number Publication Date
KR20110011676A true KR20110011676A (ko) 2011-02-08

Family

ID=41319035

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107027786A Withdrawn KR20110011676A (ko) 2008-05-13 2009-05-13 항-ＰｉｒＢ 항체

Country Status (15)

Country Link
EP (1) EP2291405A1 (https=)
JP (1) JP2011523359A (https=)
KR (1) KR20110011676A (https=)
CN (1) CN102089327A (https=)
AR (1) AR071777A1 (https=)
AU (1) AU2009246443A1 (https=)
BR (1) BRPI0912769A2 (https=)
CA (1) CA2723430A1 (https=)
IL (1) IL209129A0 (https=)
MX (1) MX2010012299A (https=)
PE (1) PE20091969A1 (https=)
RU (1) RU2010150754A (https=)
TW (1) TW200950808A (https=)
WO (1) WO2009140361A1 (https=)
ZA (1) ZA201007976B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12534528B2 (en) 2019-12-23 2026-01-27 Lg Chem, Ltd. Anti-LILRB1 antibody and uses thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011091181A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
CA2787783A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Anti-ilt5 antibodies and ilt5-binding antibody fragments
CN108285483B (zh) * 2012-04-17 2022-04-26 梅奥医学教育和研究基金会 用于中风和缺血或缺血性病况的人抗体及其特异性结合序列
CN103130898B (zh) * 2013-01-28 2014-03-26 中国人民解放军第四军医大学 Tat-lbd-pep融合蛋白及其在治疗中枢神经系统损伤疾病中的应用
EA202091540A1 (ru) 2017-12-22 2021-03-22 Джаунс Терапьютикс, Инк. Антитела к lilrb2
CN113056483B (zh) 2018-07-09 2025-08-01 戊瑞治疗有限公司 结合到ilt4的抗体
CN109439661B (zh) * 2018-10-22 2020-10-23 西安医学院 抑制pirB表达的短发卡shRNA、慢病毒及其应用
MY209480A (en) 2020-05-01 2025-07-11 Ngm Biopharmaceuticals Inc Ilt-binding agents and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL374463A1 (en) * 2001-11-14 2005-10-17 Immunex Corporation Modulation of lir function to treat rheumatoid arthritis
CA2637786A1 (en) * 2006-01-23 2007-08-16 President And Fellows Of Harvard College Compositions and methods for enhancing neuronal plasticity and regeneration

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12534528B2 (en) 2019-12-23 2026-01-27 Lg Chem, Ltd. Anti-LILRB1 antibody and uses thereof

Also Published As

Publication number Publication date
AU2009246443A1 (en) 2009-11-19
CA2723430A1 (en) 2009-11-19
MX2010012299A (es) 2010-12-06
PE20091969A1 (es) 2010-01-15
TW200950808A (en) 2009-12-16
EP2291405A1 (en) 2011-03-09
ZA201007976B (en) 2012-02-29
JP2011523359A (ja) 2011-08-11
IL209129A0 (en) 2011-01-31
WO2009140361A1 (en) 2009-11-19
BRPI0912769A2 (pt) 2015-10-13
RU2010150754A (ru) 2012-06-20
AR071777A1 (es) 2010-07-14
CN102089327A (zh) 2011-06-08

Similar Documents

Publication Publication Date Title
US20250092144A1 (en) Methods of use of anti-sortilin antibodies for treating a disease, disorder, or injury
US7384632B2 (en) Agonist anti-trk-C monoclonal antibodies
KR20110011676A (ko) 항-ＰｉｒＢ 항체
US7943329B2 (en) Modulators of neuronal regeneration
KR20100018523A (ko) ＣＲＩｇ 길항제
US20090232794A1 (en) Modulators of neuronal regeneration
US20090285803A1 (en) ANTI-PirB ANTIBODIES
US20100047232A1 (en) Modulators of neuronal regeneration
EA043015B1 (ru) Антитела против сортилина и способы их применения
ZA200210086B (en) Agonist Anti-TRK-C monoclonal antibodies.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20101210

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid